M. Kostinov, Valentina B. Polishchuk, A. A. Ryzhov, K. Mashilov, Natalia A. Karchevskaia, A. Vlasenko
{"title":"疫苗诱导肺移植候选者产生百日咳免疫力","authors":"M. Kostinov, Valentina B. Polishchuk, A. A. Ryzhov, K. Mashilov, Natalia A. Karchevskaia, A. Vlasenko","doi":"10.15690/vramn8377","DOIUrl":null,"url":null,"abstract":"Background. Given the high prevalence of Bordetella pertussis, patients with respiratory disorders are at risk of getting infected with this pathogen and developing pertussis. Therefore, they should be considered a target group for vaccination against this infection. \nAims — the objective of the study was to assess vaccine-induced immunity against pertussis in lung transplant candidates. \nMethods. Twenty-four patients with severe bronchopulmonary diseases, aged 18 to 60, were vaccinated against pertussis with Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine. Five patients underwent lung transplantation. Immunoglobulin G (IgG) antibodies (Abs) were measured using the RIDASCREEN® Bordetella IgG test system. \nResults. In the post-vaccination period, only 8.3% of the patients developed such local reactions as tenderness and induration at the injection site. The proportions of patients who were seropositive for pertussis before vaccination, one month and one year after vaccination were 71, 100 and 100%, respectively (p = 0.02). A significant increase in anti-pertussis IgG Ab levels was identified one month after a single vaccine dose, and was still observed after 12 months. In the group of two-dose vaccination, there was no statistical difference between the levels of IgG Abs one month after the first dose and one month after the second dose. A significant increase in anti-Bordetella pertussis IgG Ab levels was observed in the group of initially seronegative patients compared to seropositive patients (p = 0.03). A year after vaccination, there was no statistically significant difference in IgG Ab levels between the patients with and without a history of lung transplantation. \nConclusions. The majority (71%) of patients with severe bronchopulmonary disease was seropositive for B. pertussis. Single-dose vaccination against pertussis was safe; it induced the production of additional specific Abs and an increase in their levels in all patients. Therapy administered after lung transplantation did not significantly affect the levels of vaccine-induced Abs.","PeriodicalId":178392,"journal":{"name":"Annals of the Russian academy of medical sciences","volume":"38 8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Vaccine-Induced Immunity Against Pertussis in Lung Transplant Candidates\",\"authors\":\"M. Kostinov, Valentina B. Polishchuk, A. A. Ryzhov, K. Mashilov, Natalia A. Karchevskaia, A. Vlasenko\",\"doi\":\"10.15690/vramn8377\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background. Given the high prevalence of Bordetella pertussis, patients with respiratory disorders are at risk of getting infected with this pathogen and developing pertussis. Therefore, they should be considered a target group for vaccination against this infection. \\nAims — the objective of the study was to assess vaccine-induced immunity against pertussis in lung transplant candidates. \\nMethods. Twenty-four patients with severe bronchopulmonary diseases, aged 18 to 60, were vaccinated against pertussis with Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine. Five patients underwent lung transplantation. Immunoglobulin G (IgG) antibodies (Abs) were measured using the RIDASCREEN® Bordetella IgG test system. \\nResults. In the post-vaccination period, only 8.3% of the patients developed such local reactions as tenderness and induration at the injection site. The proportions of patients who were seropositive for pertussis before vaccination, one month and one year after vaccination were 71, 100 and 100%, respectively (p = 0.02). A significant increase in anti-pertussis IgG Ab levels was identified one month after a single vaccine dose, and was still observed after 12 months. In the group of two-dose vaccination, there was no statistical difference between the levels of IgG Abs one month after the first dose and one month after the second dose. A significant increase in anti-Bordetella pertussis IgG Ab levels was observed in the group of initially seronegative patients compared to seropositive patients (p = 0.03). A year after vaccination, there was no statistically significant difference in IgG Ab levels between the patients with and without a history of lung transplantation. \\nConclusions. The majority (71%) of patients with severe bronchopulmonary disease was seropositive for B. pertussis. Single-dose vaccination against pertussis was safe; it induced the production of additional specific Abs and an increase in their levels in all patients. Therapy administered after lung transplantation did not significantly affect the levels of vaccine-induced Abs.\",\"PeriodicalId\":178392,\"journal\":{\"name\":\"Annals of the Russian academy of medical sciences\",\"volume\":\"38 8\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of the Russian academy of medical sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15690/vramn8377\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of the Russian academy of medical sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15690/vramn8377","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景。鉴于百日咳博德特氏菌的高流行率,呼吸系统疾病患者有感染这种病原体并发展成百日咳的风险。因此,他们应被视为百日咳疫苗接种的目标群体。目的--本研究旨在评估肺移植候选者接种疫苗后产生的百日咳免疫力。研究方法24名年龄在18至60岁之间的严重支气管肺疾病患者接种了白喉、破伤风类毒素和无细胞百日咳疫苗。五名患者接受了肺移植手术。使用 RIDASCREEN® Bordetella IgG 检测系统检测免疫球蛋白 G (IgG) 抗体 (Abs)。结果显示在接种疫苗后,只有 8.3% 的患者在注射部位出现触痛和压痛等局部反应。接种前、接种一个月后和接种一年后百日咳血清阳性患者的比例分别为 71%、100% 和 100%(p = 0.02)。单剂疫苗接种一个月后,抗百日咳 IgG Ab 水平明显升高,12 个月后仍可观察到这一现象。在两剂接种组中,第一剂接种一个月后和第二剂接种一个月后的 IgG Ab 水平没有统计学差异。与血清反应阳性患者相比,最初血清反应阴性患者组的抗百日咳博德特氏菌 IgG Ab 水平明显升高(p = 0.03)。接种疫苗一年后,有肺移植史和没有肺移植史的患者之间的 IgG Ab 水平没有明显的统计学差异。结论大多数(71%)严重支气管肺病患者的百日咳杆菌血清反应呈阳性。单剂量百日咳疫苗接种是安全的;它能诱导所有患者产生额外的特异性抗体并提高其水平。肺移植后进行的治疗对疫苗诱导的抗体水平没有明显影响。
Vaccine-Induced Immunity Against Pertussis in Lung Transplant Candidates
Background. Given the high prevalence of Bordetella pertussis, patients with respiratory disorders are at risk of getting infected with this pathogen and developing pertussis. Therefore, they should be considered a target group for vaccination against this infection.
Aims — the objective of the study was to assess vaccine-induced immunity against pertussis in lung transplant candidates.
Methods. Twenty-four patients with severe bronchopulmonary diseases, aged 18 to 60, were vaccinated against pertussis with Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine. Five patients underwent lung transplantation. Immunoglobulin G (IgG) antibodies (Abs) were measured using the RIDASCREEN® Bordetella IgG test system.
Results. In the post-vaccination period, only 8.3% of the patients developed such local reactions as tenderness and induration at the injection site. The proportions of patients who were seropositive for pertussis before vaccination, one month and one year after vaccination were 71, 100 and 100%, respectively (p = 0.02). A significant increase in anti-pertussis IgG Ab levels was identified one month after a single vaccine dose, and was still observed after 12 months. In the group of two-dose vaccination, there was no statistical difference between the levels of IgG Abs one month after the first dose and one month after the second dose. A significant increase in anti-Bordetella pertussis IgG Ab levels was observed in the group of initially seronegative patients compared to seropositive patients (p = 0.03). A year after vaccination, there was no statistically significant difference in IgG Ab levels between the patients with and without a history of lung transplantation.
Conclusions. The majority (71%) of patients with severe bronchopulmonary disease was seropositive for B. pertussis. Single-dose vaccination against pertussis was safe; it induced the production of additional specific Abs and an increase in their levels in all patients. Therapy administered after lung transplantation did not significantly affect the levels of vaccine-induced Abs.